approval
saveMOUNJARO (TIRZEPATIDE) — FDA approval
community read0 votes
Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalZEPBOUND (TIRZEPATIDE) — FDA approvalFeb 25, 2026 · 226d ago
- approvalZEPBOUND (TIRZEPATIDE) — FDA approvalJan 20, 2026 · 262d ago
- approvalMOUNJARO (TIRZEPATIDE) — FDA approvalJan 20, 2026 · 262d ago
- approvalZEPBOUND (TIRZEPATIDE) — FDA approvalJan 7, 2026 · 275d ago
- approvalMOUNJARO (TIRZEPATIDE) — FDA approvalJan 7, 2026 · 275d ago
- approvalMOUNJARO (TIRZEPATIDE) — FDA approvalDec 19, 2025 · 294d ago
- approvalZEPBOUND (TIRZEPATIDE) — FDA approvalSep 25, 2025 · 379d ago
- approvalMOUNJARO (TIRZEPATIDE) — FDA approvalMay 28, 2025 · 499d ago
same company · ±60 days · 6
- approvalimlunestrant tosylate: INLURIYO (IMLUNESTRANT TOSYLATE) — FDA approvalSep 25, 2025
- approvalZEPBOUND: ZEPBOUND (TIRZEPATIDE) — FDA approvalSep 25, 2025
- approvalmirikizumab: OMVOH (MIRIKIZUMAB-MRKZ) — FDA approvalOct 23, 2025
- approvallebrikizumab: EBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approvalOct 28, 2025
- approvalselpercatinib: RETEVMO (SELPERCATINIB) — FDA approvalNov 20, 2025
- approvalselpercatinib: RETEVMO (SELPERCATINIB) — FDA approvalNov 20, 2025
comments(0)
5-min edit window · permanent after that